Phase II trial of exemestane in combination with fulvestrant in postmenopausal women with advanced, hormone-responsive breast cancer.

Mrózek, Ewa; Layman, Rachel; Ramaswamy, Bhuvaneswari; Schaaf, Larry; Li, Xiaobai; Ottman, Susan; Shapiro, Charles L

Mrózek, Ewa; Layman, Rachel; Ramaswamy, Bhuvaneswari; Schaaf, Larry; Li, Xiaobai; Ottman, Susan; Shapiro, Charles L.

Affiliation

Mrózek E; Division of Medical Oncology, The Ohio State University Medical Center, Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Columbus, OH 43210, USA. ewa.mrozek@osumc.edu

Clin Breast Cancer ; 12(2): 151-6, 2012 Apr.

Article in En | MEDLINE | ID: mdl-22444722

Subject(s)

Antineoplastic Combined Chemotherapy Protocols/therapeutic use; Breast Neoplasms/drug therapy; Adult; Aged; Aged, 80 and over; Androstadienes/administration & dosage; Androstadienes/adverse effects; Androstadienes/pharmacokinetics; Estradiol/administration & dosage; Estradiol/adverse effects; Estradiol/analogs & derivatives; Estradiol/pharmacokinetics; Female; Fulvestrant; Humans; Insulin-Like Growth Factor Binding Protein 3/blood; Insulin-Like Growth Factor I/analysis; Middle Aged; Postmenopause; Receptors, Estrogen/biosynthesis; Receptors, Progesterone/biosynthesis

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms / Antineoplastic Combined Chemotherapy Protocols Limits: Adult / Aged / Aged80 / Female / Humans / Middle aged Language: En Journal: Clin Breast Cancer Journal subject: NEOPLASIAS Year: 2012 Document type: Article Affiliation country: United States

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google